New Data, New Directions: Neladalkib (NVL-655) and Precision Oncology in ALK-Positive Cancer
Alexander Drilon, MD, is a thoracic oncologist and Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center, with research focused on ALK-positive cancers. In this ALKtALK, Dr. Drilon discusses the latest clinical data on neladalkib (NVL-655). The conversation explores emerging efficacy and safety findings and provides insight into how promising therapies move from clinical trials toward broader patient access. Dr. Drilon also shares perspective from his ongoing research, highlighting how translational science and biomarker-driven approaches continue to shape treatment strategies in ALK-positive lung cancer. This data-driven discussion focuses on where the science stands today—and where it may be headed next for patients and families navigating ALK-positive disease. The recording includes audience questions from the live session, offering additional context and practical insight. Whether you are newly diagnosed, currently in treatment, exploring clinical trials, or supporting someone you love, this ALKtALK is designed to help you stay informed and connected to the research shaping our community. Subscribe to the ALK Positive YouTube channel for future ALKtALK recordings and research updates. + + About our ALKtALKs and ALK Positive Inc + + + ALK Positive does not endorse specific treatments and does not provide medical advice. Questions and concerns should be raised with individual care teams. ALK Positive is a 501(c)(3)-registered, patient-driven organization that seeks a cure for ALK+ cancer and works to improve patients’ quality of life and life expectancy worldwide. ALK Positive is committed to raising funds for research proposals that will transform ALK-positive cancer into a chronic or curable condition for all patients living with this disease. We offer a full range of Healing Arts classes to help our community balance a productive life, treatment side effects and the mental stress of a cancer diagnosis. These include ALKtALKs -- our flagship community program aimed at making our ALK community a little smarter and a little smaller, by bringing the latest information, research and practices from leading experts. For more information about us, go to www.alkpositive.org. To donate 💖 go to https://www.alkpositive.org/ways-to-give 📢 Follow us on social media & join the conversation online! Facebook 📘 / alkpositivecancer Instagram 📸 / alkpositiveinc LinkedIn 💼 / alkpositivecancer X (Twitter) ✖️ https://x.com/ALKPositiveinc TikTok 🎵 / alkpositiveinc BlueSky ☁️ https://bsky.app/profile/alkpositive....

Navigating Brain Progression in ALK-positive Cancer: TKIs, Radiation, LMD, and More

Small Cell SMASHERS Fireside Chat with Dr. Charles Rudin

Your Holiday Toolkit: Managing Balance, Boundaries, and Expectations.

Evolving future of theranostics–the practice in Peter MacCallum cancer center byProf. Michael Hofman

RASolute-302 with Daraxonrasib - Game Changer at ASCO 2026 in Pancreatic Cancer

Unlock More Donor Heart Opportunities with Imaging You Already Have

Inside the Pipeline: TRI-611 and ALK-positive Treatment Strategies

Advancing Research Elevating Hope: A Conversation with Dr. Alice Shaw

Why Can’t We Cure Cancer? A National Conversation | Full CUOMO Special Edition 2/27

RASolute 302 Pancreatic Cancer Study with Daraxonrasib at ASCO 2026 – Dr. Brian Wolpin

"This Food Can Repair DNA & Starve Cancer!" - What You NEED TO KNOW!

Navigating ALK-positive Clinical Trials: Facts, Timelines & Real Expectations

Treating Melasma Effectively for All Skin Types

From Evidence to Impact: Leveraging the Latest Data to Elevate Standards and Outcomes in mHSPC

Dr. Christine Lovly Joins ALKtALK from the American Society of Clinical Oncology

Can a keto diet eliminate cancer growth? Dr. Thomas Seyfried says yes

Fueling the Breakthrough: ALK Positive Research and Medical Committee Update with Dr. Ken Culver

Making a Diagnosis of PSP, CBD, or MSA

Update on CLL/SLL | Lymphoma Research Foundation Webinars

